Tevogen Bio Considers Acquisition of Apozeal to Enhance Generics Strategy
Tevogen Bio has signed a non-binding Letter of Intent to explore acquiring Apozeal Pharmaceutical, which could enhance its generics platform with several FDA-approved products. If successful, this acquisition may significantly bolster Tevogen's revenue-generating capabilities and support its mission to strengthen domestic pharmaceutical manufacturing.
View signal analysis